How Johnson & Johnson is Innovating its Organizational Infrastructure
At DPHARM 2024, Johnson & Johnson’s representatives, Gordon Gregory III, and Laszlo Vasko, unveiled their transformative “Team of Teams”...
Tempus Q3 2024 Results & Ambry Acquisition
Tempus AI, Inc. (NASDAQ: TEM), a technology company driving AI adoption in precision medicine and patient care, released its...
Immunis Studies Canine Muscle Atrophy
Immunis, a clinical-stage biotech company, has launched non-terminal safety studies for canine muscle atrophy in partnership with VetBio Partners....
Enveric Biosciences: Broad Range of Patents Issued
Enveric Biosciences, a biotechnology company focused on developing novel neuroplastogens for neuropsychiatric disorders, has significantly expanded its patent protection....
Vertex Reports Strong Q3 2024 Financial Results
Vertex Pharmaceuticals reported strong third-quarter 2024 financial results and raised its full-year product revenue guidance. The company anticipates continued...
Allurion’s Obesity Data from 19,428 Patients Revealed
Allurion Technologies, a company focused on combating obesity, presented two abstracts at Obesity Week 2024. The first abstract showcased...
Scholar Rock Announces Preclinical Data for SRK-439
Scholar Rock, a late-stage biopharmaceutical company, has released promising preclinical data for SRK-439, an investigational anti-myostatin antibody. The data...
MedinCell & Teva: Olanzapine LAI Phase 3 Positive, Uzedy Real-World Data
Medincell‘s long-acting injectable technology, BEPO®, has achieved commercial success with its first product, UZEDY® (risperidone LAI), for treating schizophrenia...
CINFINA Pharma Unveils Promising Phase 1 Obesity Drug Data at ObesityWeek® 2024
CinFina Pharma, a CinRx portfolio company focused on obesity treatments, has released promising interim data from a Phase 1...
Mood Bloom™ Delivers ROI in New Economic Study
Hedonia, a mobile mental health solutions provider, has released promising findings from a recent economic model. The study, conducted...